Event

Basic research conducted by several laboratories has led to major advances in the management of COPD, Cystic Fibrosis and other airway disorders. Since lung transplantation is effective for severe COPD and CF, technologies to expand availability of donor lungs can be transformative for patients. This session will present the basic findings which underscore the use of mepolizumab for eosinophilic COPD, CFTR potentiators for cystic fibrosis and ex vivo lung perfusion and ECMO to rescue nonideal donor lungs for transplantation and avail tolerance for long wait list times. The clinical utility of these findings, complementing basic narratives, will show how primary discovery propels clinical advances for airway disorders.